ChromaDex

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ChromaDex reports record revenue and eyes growth through partnerships

ChromaDex's strong revenue growth and positive EBITDA reflect operational improvements.
The company faces challenges in sales channels and marketing claims but sees growth opportunities.
Strategic focus on new partnerships, product development, and pharmaceutical initiatives for future growth.

ChromaDex reports robust Q1 performance, eyes innovation for growth

ChromaDex's Q1 2023 performance was strong, with notable growth in revenue and positive cash flows. The company faces challenges in recurring revenue conversion and aims for improved financial metrics. However, opportunities lie in innovation, R&D, and potential partnerships for future growth.

ChromaDex reports strong Q2 earnings and eyes market expansion

ChromaDex's Q2 performance reflects robust revenue growth, strong partnerships, and a commitment to scientific excellence, positioning the company for continued success.
While facing challenges such as customer retention and working capital management, ChromaDex remains focused on profitability and strategic investments for future growth.
Opportunities in expanding market share, leveraging key partnerships, and enhancing customer loyalty present avenues for sustained revenue growth and market leadership.
With a solid financial position and a balanced approach to growth, ChromaDex is poised to navigate challenges and capitalize on opportunities in the evolving market landscape.

ChromaDex reports robust Q3 results, eyes growth through strategic partnerships

ChromaDex's Q3 performance reflects revenue growth, profitability, and operational efficiency, supported by strong financials and strategic partnerships.
The company's focus on innovation, market expansion, and cost control measures positions it well for sustained growth and competitive advantage.
While facing challenges in a dynamic market environment, ChromaDex's opportunities lie in product innovation, market diversification, and strategic partnerships.
Overall, ChromaDex's strategic initiatives and financial strength indicate a positive outlook for future growth and market expansion.

ChromaDex reports robust earnings, eyes growth through partnerships and innovation

ChromaDex delivered strong financial performance in Q4 2023 and full year 2023, driven by revenue growth, partnerships, and product demand.
While facing challenges in meeting consumer demand and optimizing resource allocation, the company remains focused on responsible practices and future growth opportunities.
With a solid financial foundation, strategic partnerships, and a focus on innovation, ChromaDex is poised for continued growth and market leadership in the dietary supplement industry.

ChromaDex reports revenue growth and strategic partnerships for future expansion

ChromaDex's Q1 2024 performance reflects revenue growth, positive EBITDA, and strategic initiatives for future expansion.
The company's strengths lie in subscriber base building, successful product SKUs, and stable market presence in key segments.
While facing challenges such as increased expenses and short-term R&D investments, ChromaDex is well-positioned for growth.
Opportunities in new partnerships, product development, and market exploration offer avenues for revenue growth and enhanced customer value.

ChromaDex reports revenue growth and product innovation in Q2

ChromaDex's Q2 2024 performance showed revenue growth, positive EBITDA, and a strong cash position.
The company's strengths lie in its innovative NIAGEN product line and positive clinical study outcomes.
Challenges include market misinformation and the need to adjust outlook due to product delays.
Opportunities exist in addressing specific health conditions and leveraging marketing strategies for growth.

ChromaDex (CDXC) reports record Q3 results and eyes growth

ChromaDex (CDXC) delivers strong Q3 performance with record revenue and profitability, driven by e-commerce and product launches.
Despite challenges in outlook adjustment and pricing strategies, the company's financial discipline and market focus position it for growth.
Opportunities lie in expanding product reach, FDA approvals, and strategic marketing to capitalize on market potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #IPNews--ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted an additional continuation patent, U.S. Patent No. 11,274,117, adding to its global patent portfolio surrounding nicotinamide riboside (NR) and other nicotinamide adenine dinucleotide (NAD) precursors. This newly granted continuation patent reinforces U.S. Patent No. 11,242,364, which was just granted to ChromaDex on February 8, 2022 (full press release here). ChromaDex currently owns and licenses a

ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations

ChromaDex Corporation (CDXC) CEO Rob Fried on Q4 2021 Results - Earnings Call Transcript

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2021 financial results. Fourth Quarter 2021 and Recent Highlights Total net sales were $17.8 million, up 15% year over year. Tru Niagen® net sales were $14.1 million, a 14% increase year over year. Gross margin was 61.2%, up 20 basis points year over year. Net loss was $5.3 million or $0.08 loss per share, an improvement of $0.02 per share year over year. In January 2022, announced a suppl

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #clinicalresearch--ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study, as reported in the peer-reviewed journal Cell Metabolism by a team of scientists led by Prof. Charalampos Tzoulis, Haukeland University Hospital and University of Bergen, in Norway. The clinical trial was part of the ChromaDex External Research Program (CERP™) and investigated the company's proprietary Niagen® ingredient (patented nicotinamide riboside, or “NR”

ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study Analyzing the Promising Effect of Nicotinamide Riboside (NR) Supplementation in Patients with Parkinson's Disease (PD)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. March 9, 2022 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended December 31, 2021. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the fourth quarter results

ChromaDex to Report Fourth Quarter 2021 Financial Results on Wednesday, March 9, 2022

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #IPNews--ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted a continuation patent, adding to its global patent portfolio surrounding nicotinamide riboside (NR) and other nicotinamide adenine dinucleotide (NAD) precursors. ChromaDex currently holds a robust patent portfolio of over 40 granted or licensed patents relating to Niagen® (patented NR) and other precursors to NAD, a molecule at the forefront of the healthy aging and cellular health categories. Niagen

ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #niagen--ChromaDex Corp. (NASDAQ:CDXC) celebrates the ChromaDex External Research Program's (CERP™) 100th published peer-reviewed study on the company's flagship ingredient Niagen® (patented nicotinamide riboside, or “NR”) and other proprietary ingredients. CERP, the program pioneering NR research, is the first-of-its-kind to reach such a milestone. The recently published preclinical trial in the Investigative Ophthalmology & Visual Science Journal investigated the effe

ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ClinicalResearch--ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen® (patented nicotinamide riboside, or “NR”) ingredient with promising, peer-reviewed findings reported in the Journal of Clinical Investigation. The study investigated the anti-inflammatory effects of ChromaDex's proprietary NR ingredient in monocytes (a type of white blood cell) extracted from two groups: young, healthy subjects and patients diagnosed with system

ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation

ChromaDex Corp (NASDAQ:CDXC) has announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs).  ChromaDex's proprietary healthy aging ingredient Niagen will be added to multi-ingredient Designs for Health formulas.

ChromaDex Shares Gain On Niagen Supply Pact With US-Based Provider Of Dietary Supplements

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs). ChromaDex's proprietary healthy aging ingredient Niagen®, the world's first and only FDA-safety reviewed and patented form of nicotinamide riboside, will be added to multi-ingredient Designs for Health formulas. The new products will be available exclusively through the company's exte

ChromaDex and Designs for Health Partner for New Product Development on Niagen®

ChromaDex Corporation (CDXC) CEO Rob Fried on Q3 2021 Results - Earnings Call Transcript

ChromaDex (CDXC) delivered earnings and revenue surprises of -30.00% and 0.76%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q3 Loss, Tops Revenue Estimates

ChromaDex (NASDAQ:CDXC) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:02 PM. Here's what investors need to know about the announcement.

Recap: ChromaDex Q3 Earnings

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2021. Third Quarter 2021 and Recent Highlights Total net sales were $17.3 million, up 22% from the prior year quarter. Tru Niagen® net sales were $14.8 million, a 24% increase from the prior year quarter. Gross margin was 61.1%, a 150 basis point increase from the prior year quarter. Net loss was $(8.9) million or $(0.13) per share, a decline of $0.06 per share from the prior y

ChromaDex Corporation Reports Third Quarter 2021 Financial Results

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate ChromaDex (CDXC) to Report a Decline in Earnings: What to Look Out for

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ataxia--ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study published in the peer-reviewed journal, Movement Disorders, conducted by Michèl A.A.P. Willemsen MD, PhD of Radboud University Medical Center. The study investigated ChromaDex's proprietary Niagen® ingredient (patented nicotinamide riboside, or “NR”) in patients with ataxia-telangiectasia (AT), a rare, inherited neurodegenerative disorder characterized by premat

ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wednesday, Nov. 3, 2021 at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sep. 30, 2021. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the third quarter results

ChromaDex to Report Third Quarter 2021 Financial Results on Wednesday, Nov. 3, 2021

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #cdxc--ChromaDex Corp. (NASDAQ:CDXC) today announced that a jury in the United States District Court for the Central District of California found that Elysium Health, Inc. (“Elysium”) breached its contract with ChromaDex by failing to pay for product it ordered and received in 2016. Based on the jury's verdict, Elysium and Mark Morris will be required to pay ChromaDex approximately $2.25 to $2.50 million in damages and estimated interest. “It took nearly five years and ha

ChromaDex Comments on Jury Award Against Elysium Health and Reiterates Plans for Growth

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChinaCrossBorder--ChromaDex Corp. (NASDAQ: CDXC) announced today a partnership with Sinopharm Xingsha Pharmaceuticals (Xiamen) Co., Ltd. (“Sinopharm Xingsha”) to conduct cross-border sales of Tru Niagen® in mainland China. Sinopharm Xingsha is a subsidiary of Sinopharm Group, with businesses including pharmaceutical manufacturing, marketing and distribution of drugs, and food supplements and healthcare products. It is the main platform of Sinopharm Group for food supplements and hea

ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #nicotinamideriboside--ChromaDex Corp. (NASDAQ:CDXC) today announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen® (patented nicotinamide riboside, or “NR”) in various health outcomes. Through the industry-leading ChromaDex External Research Program (CERP™), ChromaDex supplies Niagen® to researchers around the world at no cost to help advance the understanding of NR's impact on various age-related health cond

ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™)

The company lost a key patent infringement lawsuit but plans to appeal the court decision.

Why ChromaDex Stock Is Sinking Today

The stock price of ChromaDex Corp. (NASDAQ: CDXC) dropped over 20% pre-market today. This is why it happened.

CDXC Stock: Why It Significantly Dropped Today

ChromaDex Corp (NASDAQ: CDXC) dropped over 20% during the premarket despite its announcement over plans to appeal a court ruling issued by the U.S. District Court for the District of Delaware in a patent infringement lawsuit against Elysium Health. Related:   ChromaDex Shares Jump on Tru Niagen's Launch In Walmart Stores.

Why Are ChromaDex Shares Trading Lower On Wednesday?

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) issued the following statement: ChromaDex announced today plans to appeal a September 14 decision granting a Motion for Summary Judgment (MSJ) in its lawsuit for patent infringement against Elysium Health, Inc. (“Elysium”) in the United States District Court for the District of Delaware. ChromaDex licenses U.S. Patent No. 8,383,086 (“the '086 patent”) and U.S. Patent No. 8,197,807 (“the '807 patent”) from the Trustees of Dartmouth Coll

ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge's Ruling in Patent Infringement Lawsuit

ChromaDex Corporation (CDXC) CEO Rob Fried on Q2 2021 Results - Earnings Call Transcript

News for ChromaDex Stock (CDXC)